TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 7; p. 632
• Main Author: Han, Sun-Young
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29.06.2021; MDPI
• Subjects: Biomarkers; Cancer therapies; entrectinib; FDA approval; larotrectinib; Mutation; NTRK; Review; tissue-agnostic; Trk; Trk fusion

Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type...